Elicio Therapeutics, Inc. · NASDAQ:ELTX
Elicio Therapeutics — Angion Biomedica — Merger or Acquisition (January 2023)
22 slides from Elicio Therapeutics's merger presentation, Jan 18, 2023
Slide 1: Unlocking the Potential of Immunotherapy
c Unlocking the 3 e| ICIO Potential of THERAPEUTICS Immunotherapy January 2023
Slide 2: Additional Information and Where to Find It
Additional Information and Where to Find It Angion Biomedica plans to file with the SEC, and the parties plan to furnish to the security holders of Elicio Therapeutics and Angion Biomedica, a Registration Statement on Form S-4, which will constitute a prospectus and proxy statement of Angion Biomedi
Slide 3: Merger terms: equity split, valuations, net cash, bridge loan
DM1 Equity Split The expected equity split at Closing is approximately 34.5% held by Next Steps Angion stockholders and approximately 65.5% by Elicio stockholders ona fully diluted basis* Form S-4 Valuations Elicio = $95,000,000 / Angion = $50,050,000 Proxy Process Conversion of Shares Each share of
Slide 4: AMP technology delivers payloads directly to the lymph nodes
..and while they are critical to orchestrating the immune response, most immunotherapies don’t directly interact within the lymph nodes, limiting their efficacy AMP technology delivers payloads directly to the lymph nodes... ..leading to immune responses with increased magnitude, potency, and durabi
Slide 5: A Unique Immuno-Oncology Opportunity
A Unique Immuno-Oncology Opportunity ELI-002, a lymph-node targeted therapeutic mutant KRAS vaccine, has begun enrollment of the fifth cohort of a P1 dose escalation trial in adjuvant-stage colorectal and pancreatic cancer patients ELI-002 is designed to stimulate an immune response against the 7 KR
Slide 6: ELI-002 Targets KRAS Mutations That Drive 25% of Solid Tumors
ELI-O02 Targets 7 KRAS Mutations That Drive 25% of Solid Tumors Creating a Multi-Billion Dollar Opportunity 21% Bile Duct Cancer / Cholangiocarcinoma (CCA) Non-Small Cell Lung US Incidence: “8k Cancer (NSCLC) US Incidence: “195k Pancreatic Ductal Adenocarcinoma (PDAC) US Incidence: “56k L = i} \ 5%
Slide 7: ELI-002: AMP KRAS
ELI-O02: AMP KRAS = i Elicio Non -Confidential 1
Slide 8: ELI-002 Is Poised To Overcome Historical Challenges Of Cancer Vaccines
ELI-OO2 Is Poised To Overcome Historical Challenges Of Cancer Vaccines While past oncology vaccine efforts have struggled to induce a sufficient immune response, ELI-002 has a twepronged strategy to induce potent antitumor immune activity: Technological Innovation: AMP Platform Smart trafficking to
Slide 9: The Phase 1 AMPLIFY-201 Trial Includes a Variety of mKRAS/mNRAS Tumors
The Phase | AMPLIFY-201 Trial Includes a Variety of mMKRAS/mNRAS Tumors in EarlyStage Disease Adjuvant Therapy in Basket larly Stage KRAS/NRAS Mutatedancers witiMRD + Early-stage disease (not advanced) + MRD+ (ctDNA/serum tumor biomarkers) + mRAS/mNRAS (612D/R for AMPLIFY - 201 ~ all 7 peptides for
Slide 10: Biologic Markers are Critical Components to Track Patient Progress
Biologic Markers are Critical Components to Track Patient Progress in the Adjuvant Stage For Radiographic endpoints have limitations in measuring the effect of Endpoi immuno-oncology drugs, including atypical patterns of response and pseudo-progression leading to inaccuracy © KRAS T cell activity *
Slide 11: AMPLIFY-201 Dose Escalation Designed to Determine Phase 2 Dose
© © ® @ © AMPLIFY-201 Dose Escalation Designed to Determine Phase 2 Dose and Provide Proof of Concept ELI-002 2 peptide formulation (2P) comprised of admixed AMP-CpG and mutated AMP -KRAS/NRAS peptides Interim clinical data from KRAS+ pancreatic and colorectal cancer patients anticipated to be prese
Slide 12: ELI-002 Clinical Program Milestone Projections
ELI-O02 Clinical Program Milestone Projections: Ph1 Data Readout 2023 & Ph2 Interim Assessment 202 © AMPLIF¥-201 (£14002 2P Formulation) (@ AMPLIFY7P (ELI -002 7P Formulation) Phi IA (PDAC/CRC) Study Initiation Philb Cohorts Open AtN=9 ** Ph1/2 six patient 7P safety rim ras . Randomized Ph2 Opens***
Slide 13: AMP Platform & Pipeline Overview
AMP Platform & Pipeline Overview = i 1. Elicio Non -Confidential 7
Slide 14: Immune Response is Orchestrated in the Lymph Nodes
Immune Response is Orchestrated in the Lymph Nodes N The Immune “Schoolhouse” Numerous Immune Cells Response Coordination APC : T Cell Interaction 7
Slide 15: AMP Reprograms Biodistribution to Promote Targeted Delivery
AMP Reprograms Biodistribution to Promote Targeted Delivery of Payloads (e.g., Antigens, Adjuvants) to Lymph Nodes Tissue Injection Site Molecular Size Drives Lymphatic Targeting Blood Vessel 1 t 120 @ @ o Albumin systemic » 100 eg bleed circulation a Aaa 3 Z eS = 80 ° C) Ss ie 3 a oelee 2 i; Small
Slide 16: Modular Conjugation Approach Allows for Delivery of a Wide Variety of Payloads
Modular Conjugation Approach Allows for Delivery of a Wide Variety of Payloads to the Lymph Nodes Polymeric Linker Q Improve Solubility © control Payload Release ) Lymph Node Targeting © antigens . 1 © adjuvants 1 © Lymph Node Retention Elicio Non -Confidential 10
Slide 17: AMP-CpG E7 Protein Therapy Eradicated HPV-driven Tumors in a Preclinical Mouse Study
AMP-CpG E7 Protein Therapy Eradicated HPV-driven Tumors ina Preclinical Mouse Study e Tumor Size # 10. = 2% 2g day 0 ~~ Tumor Cells CD8T Cell Response 5° day 12 -- Dose 1 é 5 day 26 ~~ Dose 2 So am 5 * 0 ’ o day 40 -- Dose3 § g 80: 10 20 30 40 } | Monitor S 3 60: Days H ‘Tumor Size te a ££ 40. Survi
Slide 18: AMP Drives Superior Preclinical Immune Responses
AMP Drives Superior Preclinical Immune Responses * Improvedlymph node delivery over conventional therapies in mice and primates ¢ Enhanceddelivery of therapeutic cargoes to immune cellsin mice and primates * Increasedfunctional immune responsesrelative to conventional vaccines, strong immunogenicity
Slide 19: AMP Partnering Opportunities and Product Candidates
EU-007 mBRAF Undisclosed cme Eu-008 mTP53 Undisclosed | | | Fees AMP PARTNERING OPPORTUNITIES PRODUCT Rem CANDIDATE TARGET INDICATION(S) RESEARCH PRECLINICAL PHASE 1 PHASE 2 COLLABORATION PALES eLLo12 mkRAS Solid Tumors Ttsti‘“CsCsS eu-ou ow Liquid Tumors ..... Eu-005, SARS-Cov-2 coving |... . Undis
Slide 20: Regeneron and GI Research collaborations
REGENERON Clinical collaboration to study ELI-002 in combo with Regeneron’s LIBTAYO (anti-PD-L1 CPI) + REGN will supply LIBTAYO at no cost to Elicio + Multiple studies/cohorts planned across multiple tumor types and treatment settings + Elicio retains full worldwide rights to ELD02, REGN has no righ
Slide 21: Elicio Non -Confidential 45
Elicio Non -Confidential 45
Slide 22: Additional Information and Where to Find It
Additional Information and Where to Find It The transaction referenced in the above communication has not yet been consummated. This communication is for informational purposes only and is not a substitute for any materials that Angion Biomedica Corp. (“Angion”) will file with the U.S. Securities an
Angion Biomedica — Merger or Acquisition (January 2023) on 6ix